CD28 costimulation and T lymphocyte proliferative responses in HIV-1 infection

Clinical and Experimental Immunology

Volumn 109, Issue 3, 1997, Pages 406-411

  Carlesimo, M ^a   Pontesilli, O ^a,c   Varani, A R ^a   Bernardi, M L ^a   Mazzone, A M ^a   Rosso, R ^a   Guerra, E C ^a   Cassone, A ^b   Paganelli, R ^a   Aiuti, F ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^c CENTRAL LABORATORY   (Netherlands)

Author keywords

Costimulation; Gp160; HIV 1; Proliferation; T lymphocyte

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; GLYCOPROTEIN GP 160; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; T LYMPHOCYTE RECEPTOR; ZIDOVUDINE;

ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; LYMPHOCYTE COUNT; LYMPHOCYTE CULTURE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

EID: 9844240496     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1997.4721370.x     Document Type: Article

References (32)

1. Klein MR, Van Baalen CA, Holwerda AM et al. Kinetic of Gag-specific CTL responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995; 181:1365-72.
2. Lange JM, Coutinho RA, Krone WJ et al. Distinct IgG recognition patterns during progression of subclinical and clinical infection with lymphadenopathy associated virus/human T lymphotropic virus. Br Med J 1986; 292:228-30.
3. Wahren B, Morfeldt-Mansson L, Biberfeld G et al. Impaired specific cellular response to HTLV-III before other immune defects in patients with HTLV-III infection. N Engl J Med 1986; 315:393-4.
4. Wahren B, Morfeldt-Mansson L, Biberfeld G et al. Characteristics of the specific cell-mediated immune response in Human Immunodeficiency Virus infection. J Virol 1987; 61:2017-23.
5. Krowka JF, Stites DP, Jain S et al. Lymphocyte proliferative responses to human immunodeficiency virus antigens in vitro. J Clin Invest 1989; 83:1198-203.
6. Pontesilli O, Carlesimo M, Varani AR et al. HIV-specific lymphoproliferative responses in asymptomatic HIV-intected individuals. Clin Exp Immunol 1995; 100:419-24.
7. + T cell numbers and clinical staging. J Clin Invest 1989; 84:1892-9.
8. Shearer GM, Clerici M. Early T-helper cell defects in HIV infection. AIDS 1991; 5:245-53.
9. Schellekens PTA, Roos MTL, De Wolf F et al. Low T-cell responsiveness to activation via CD3/TCR is a prognostic marker for acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus-1 (HIV-1) infected men. J Clin Immunol 1990; 10:121-7.
10. Roos MTL, Miedema F, Koot M et al. T cell function in vitro is an independent progression marker for AIDS in Human Immunodeficiency Virus-infected asymptomatic subjects. J Infect Dis 1995; 171:531-6.
11. Meyaard L, Schuitemaker H, Miedema F. T-cell dysfunction in HIV infection: anergy due to defective antigen presenting cell function? Immunol Today 1993; 14:161-4.
12. June CH, Bluestone JA, Nadler LM, Thompson CB. The B7 and CD28 receptor families. Immunol Today 1994; 15:321-31.
13. Reiser H, Stadecker MJ. Costimulatory B7 molecules in the pathogenesis of infectious and autoimmune diseases. N Engl J Med 1996; 335:1369-77.
14. Linsley PS, Clark EA, Ledbetter JA. T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci USA 1990; 87:5031-5.
15. Linsley PS, Brady W, Grosmaire L et al. Binding of the B cell activation antigen B7 to CD28 costimulates T cell proliferation and interleukin 2 mRNA accumulation. J Exp Med 1991; 173:721-30.
16. Hathcock KS, Laszlo G, Dickler HB et al. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 1993; 262:905-7.
17. Harding FA, McArthur JG, Gross JA et al. CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones. Nature 1992; 356:607-9.
18. Centers for Disease Control. 1993 revised classification system for HIV, infection and expanded surveillance case definition for AIDS, among adolescents and adults. MMWR 1993; 41:1-19.
19. Guerra E, Ricci G, Carlesimo M et al. Immunological aspects of patients with HIV-1 disease following immunization with recombinant gp160 (VaxSyn). In: Development and applications of vaccines and gene therapy in AIDS. Antibiot Chemother 1996; 48:147-52.
20. Pontesilli O, Guerra EC, Ammassari A et al. A phase II controlled trial of post-exposure immunization with recombinant gp160 in comparison with antiretroviral therapy, alone or in combination, in asymptomatic HIV-1 infected patients. Submitted.
21. Schrier RD, Gnann JW, Landes R et al. T-cell recognition of HIV synthetic peptides in a natural infection. J Immunol 1989; 142:1166-76.
22. + T helper cell depletion occurs. J Clin Invest 1988; 82:1908-14.
23. + T cells by stimulation through the CD28 pathway. Clin Exp Immunol 1996; 105:225-30.
24. Meyaard L, Kuiper H, Otto SA et al. Evidence for intact costimulation via CD28 and CD27 molecules in hyporesponsive T cells from human immunodeficiency virus-infected individuals. Eur J Immunol 1995; 25:232-7.
25. Roos MTL, Miedema F, Meinesz AAP et al. Low T cell reactivity to combined CD3 plus CD28 stimulation is predictive for progression to AIDS: correlation with decreased CD28 expression. Clin Exp Immunol 1996; 105:409-15.
26. + T cells from Human Immunodeficiency Virus-infected asymptomatic individuals. J Exp Med 1992; 175:331-40.
27. Clerici M, Lucey DR, Berzofsky JA et al. Restoration of HIV-specific cell-mediated immune responses by interleukin-12 in vitro. Science 1993; 262:1721-4.
28. Landay AL, Clerici M, Hashemi F et al. In vitro restoration of T cell immune function in Human Immunodeficiency Virus-positive persons: effect of interleukin (IL)-12 and anti-IL-10. J Infect Dis 1996; 173:1085-91.
29. Manca F, Habeshaw JA, Dalgleish AG. HIV envelope glycoprotein. antigen specific T-cell responses, and soluble CD4. Lancet 1990; 335:811-5.
30. + T lymphocytes during HIV-1 infection. J Acquir Immune Defic Syndr 1994; 7:245-53.
31. Dittmer U, Luke W, Stahl-Hennig C et al. Early helper T-cell dysfunction in simian immunodeficiency virus but not in human immunodeficiency virus type-2-infected macaques. J Med Primatol 1994; 23:298-303.
32. Tacket CO, Baqar S, Munoz C, Murphy JR. Lymphoproliferative responses to mitogens and HIV-1 envelope glycoprotein among volunteers vaccinated with recombinant gp160. AIDS Res Hum Retrovir 1990; 6:535-45.